Related references
Note: Only part of the references are listed.Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Marcela V. Maus et al.
BLOOD (2014)
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
Yang Xu et al.
BLOOD (2014)
Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice
Victoria Hillerdal et al.
BMC CANCER (2014)
Engineered T cells for cancer therapy
Carl H. June et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Shannon L. Maude et al.
CANCER JOURNAL (2014)
Humanized NOD-SCID IL2rg-/- mice as a preclinical model for cancer research and its potential use for individualized cancer therapies
Qianjun Zhou et al.
CANCER LETTERS (2014)
Engineering T cells for cancer: our synthetic future
Robert H. Vonderheide et al.
IMMUNOLOGICAL REVIEWS (2014)
Design and development of therapies using chimeric antigen receptor-expressing T cells
Gianpietro Dotti et al.
IMMUNOLOGICAL REVIEWS (2014)
Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma
Markus Chmielewski et al.
IMMUNOLOGICAL REVIEWS (2014)
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells
Michael C. Jensen et al.
IMMUNOLOGICAL REVIEWS (2014)
Differential Role of Th1 and Th2 Cytokines in Autotoxicity Driven by CD19-Specific Second-Generation Chimeric Antigen Receptor T Cells in a Mouse Model
Eleanor J. Cheadle et al.
JOURNAL OF IMMUNOLOGY (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
Liang-Chuan S. Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Nature of Tumor Control by Permanently and Transiently Modified GD2 Chimeric Antigen Receptor T Cells in Xenograft Models of Neuroblastoma
N. Singh et al.
Cancer Immunology Research (2014)
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Liza B. John et al.
CLINICAL CANCER RESEARCH (2013)
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia
Eric Tran et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?
Sjoukje J. C. van der Stegen et al.
JOURNAL OF IMMUNOLOGY (2013)
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
Petra C. Schuberth et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
Sunitha Kakarla et al.
MOLECULAR THERAPY (2013)
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
Christopher C. Kloss et al.
NATURE BIOTECHNOLOGY (2013)
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
James N. Kochenderfer et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
PD-1-and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
Victor D. Fedorov et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain et al.
CANCER DISCOVERY (2013)
Isolation of Tumor Antigen-Specific Single-Chain Variable Fragments Using a Chimeric Antigen Receptor Bicistronic Retroviral Vector in a Mammalian Screening Protocol
Grazyna Lipowska-Bhalla et al.
HUMAN GENE THERAPY METHODS (2013)
Potential Limitations of the NSG Humanized Mouse as a Model System to Optimize Engineered Human T cell Therapy for Cancer
Erik M. Alcantar-Orozco et al.
HUMAN GENE THERAPY METHODS (2013)
CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors
Vanesa Alonso-Camino et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2013)
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Zakaria Grada et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2013)
Design of a Phase I Clinical Trial to Evaluate Intratumoral Delivery of ErbB-Targeted Chimeric Antigen Receptor T-Cells in Locally Advanced or Recurrent Head and Neck Cancer
May C. I. van Schalkwyk et al.
HUMAN GENE THERAPY CLINICAL DEVELOPMENT (2013)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
Brian G. Till et al.
BLOOD (2012)
Targeted immunotherapy of cancer with CAR T cells: achievements and challenges
Grazyna Lipowska-Bhalla et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy
Hui K. Gan et al.
CANCER RESEARCH (2012)
Flexible Targeting of ErbB Dimers That Drive Tumorigenesis by Using Genetically Engineered T Cells
David M. Davies et al.
MOLECULAR MEDICINE (2012)
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
John Scholler et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Comparison of Different Suicide-Gene Strategies for the Safety Improvement of Genetically Manipulated T Cells
Virna Marin et al.
HUMAN GENE THERAPY METHODS (2012)
Paths to stemness: building the ultimate antitumour T cell
Luca Gattinoni et al.
NATURE REVIEWS CANCER (2012)
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy
Carlos A. Ramos et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells
David M. Barrett et al.
HUMAN GENE THERAPY (2011)
Trafficking of CAR-Engineered Human T Cells Following Regional or Systemic Adoptive Transfer in SCID Beige Mice
Ana Caterina Parente-Pereira et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
The Tumor Lysis Syndrome
Scott C. Howard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Treating cancer with genetically engineered T cells
Tristen S. Park et al.
TRENDS IN BIOTECHNOLOGY (2011)
MAGE-A family: Attractive targets for cancer immunotherapy
Meixiang Sang et al.
VACCINE (2011)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
Tumor Ablation by Gene-Modified T Cells in the Absence of Autoimmunity
Leanne X. J. Wang et al.
CANCER RESEARCH (2010)
Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor
Yangbing Zhao et al.
CANCER RESEARCH (2010)
Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy
John S. Bridgeman et al.
CURRENT GENE THERAPY (2010)
Vaccine provides new hope for patients with deadly brain cancer
[Anonymous]
FUTURE NEUROLOGY (2010)
Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells
Eleanor J. Cheadle et al.
JOURNAL OF IMMUNOLOGY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
John H. Sampson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
CAR Mechanics: Driving T Cells into the MUC of Cancer
John Maher et al.
CANCER RESEARCH (2009)
Monoclonal antibody-induced cytokine-release syndrome
Peter J. Bugelski et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2009)
The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma
Eleanor J. Cheadle et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism
S. Muruganandan et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Differential expression profile of MAGE family in non-small-cell lung cancer
Jong-Rung Tsai et al.
LUNG CANCER (2007)
Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells
KS Kahlon et al.
CANCER RESEARCH (2004)
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1
S Hacein-Bey-Abina et al.
SCIENCE (2003)
Share Paper
